NY A10107

Amends Public Health Law Section 280-a to require pharmacy benefit managers to identify therapeutically equivalent drugs available at or below the maximum allowable cost when denying an appeal.

If the identified drug is unavailable below the pharmacy's acquisition cost from their primary wholesaler, the pharmacy benefit manager must adjust the reimbursement rate above the pharmacy's acquisition cost and permit reverse and rebill of affected claims.

Prohibits pharmacy benefit managers from reimbursing independent pharmacies or pharmacists at rates lower than they reimburse their own affiliate pharmacies for the same pharmacist services.

Requires reimbursement calculations on a per-unit basis using the same generic product identifier or generic code number.

Takes effect ninety days after enactment into law.